Published in Blood on March 16, 2009
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med (2013) 2.50
IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol (2010) 2.12
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron (2010) 1.96
Essentials of Th17 cell commitment and plasticity. Blood (2013) 1.95
Cancer-related inflammation. J Clin Immunol (2012) 1.91
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity (2013) 1.77
Deciphering the role of Th17 cells in human disease. Trends Immunol (2011) 1.76
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol (2013) 1.65
Th17 cells in cancer: help or hindrance? Carcinogenesis (2011) 1.63
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ (2013) 1.60
IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol (2010) 1.57
Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One (2011) 1.56
Interleukin-17 and its expanding biological functions. Cell Mol Immunol (2010) 1.55
In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A (2010) 1.47
IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res (2010) 1.45
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A (2010) 1.36
T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A (2014) 1.36
Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans. Blood (2011) 1.35
Th17 cells in cancer: the ultimate identity crisis. Front Immunol (2014) 1.33
Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene (2010) 1.32
Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One (2012) 1.30
The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology (2012) 1.26
Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res (2012) 1.26
TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov (2011) 1.26
Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res (2011) 1.22
STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18
Gut microbiota, immunity, and disease: a complex relationship. Front Microbiol (2011) 1.17
Bone marrow and the control of immunity. Cell Mol Immunol (2011) 1.15
The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One (2011) 1.15
IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol (2009) 1.14
IL-17 signaling in host defense and inflammatory diseases. Cell Mol Immunol (2010) 1.11
IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int (2011) 1.10
The role and regulation of human Th17 cells in tumor immunity. Am J Pathol (2012) 1.09
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One (2014) 1.05
Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol (2012) 1.03
Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer (2010) 1.03
Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood (2010) 1.03
The dual role of inflammation in colon carcinogenesis. Int J Mol Sci (2012) 1.01
IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer (2013) 1.01
IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS One (2012) 1.01
Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol (2013) 1.00
Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci U S A (2014) 1.00
Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res (2010) 0.99
The gastrointestinal tumor microenvironment. Gastroenterology (2013) 0.99
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin Exp Metastasis (2011) 0.99
The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm (2014) 0.98
Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice. PLoS One (2013) 0.95
Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage? Expert Opin Biol Ther (2011) 0.90
From mice to humans: developments in cancer immunoediting. J Clin Invest (2015) 0.90
Prognostic value of Th17 cells in acute leukemia. Med Oncol (2013) 0.89
Does IL-17 promote tumor growth? Blood (2009) 0.88
Does IL-17 suppress tumor growth? Blood (2010) 0.88
Th17 Cell Plasticity and Functions in Cancer Immunity. Biomed Res Int (2015) 0.88
Role of TH17 cytokines in the control of colorectal cancer. Oncoimmunology (2013) 0.87
Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses. J Immunol (2012) 0.87
Promotion of lung tumor growth by interleukin-17. Am J Physiol Lung Cell Mol Physiol (2014) 0.87
Therapeutical measures to control airway tolerance in asthma and lung cancer. Front Immunol (2012) 0.86
Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol (2010) 0.85
The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer. Clin Dev Immunol (2013) 0.85
T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour. Immunology (2013) 0.84
Effective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubes. Int J Nanomedicine (2011) 0.83
Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen. Cancer Immunol Immunother (2013) 0.83
Autoimmunity as a double agent in tumor killing and cancer promotion. Front Immunol (2014) 0.83
Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm (2013) 0.83
Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification. BMC Surg (2015) 0.82
CpG oligodeoxynucleotides enhance the efficacy of adoptive cell transfer using tumor infiltrating lymphocytes by modifying the Th1 polarization and local infiltration of Th17 cells. Clin Dev Immunol (2010) 0.82
Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro. Cancer Microenviron (2012) 0.82
Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta. Immune Netw (2009) 0.82
Prognostic significance of interleukin-17 in solid tumors: a meta-analysis. Int J Clin Exp Med (2015) 0.82
Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene (2016) 0.82
The Treg/Th17 paradigm in lung cancer. J Immunol Res (2014) 0.82
IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye. J Immunol (2011) 0.81
Inhibition of IL-17A suppresses enhanced-tumor growth in low dose pre-irradiated tumor beds. PLoS One (2014) 0.81
Modulation of tumorigenesis by the pro-inflammatory microRNA miR-301a in mouse models of lung cancer and colorectal cancer. Cell Discov (2015) 0.81
Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer. Inflammation (2015) 0.80
Dual role of immunomodulation by anticancer chemotherapy. Nat Med (2013) 0.80
Exploiting IL-17-producing CD4(+) and CD8(+) T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother (2016) 0.79
Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17. PLoS One (2013) 0.78
IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells. Cancer Biol Ther (2012) 0.78
IL-17A (-197G/A) and IL-17F (7488T/C) gene polymorphisms and cancer risk in Asian population: a meta-analysis. Onco Targets Ther (2014) 0.78
Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells. Cancer Gene Ther (2012) 0.78
Decreased IL-27 Negatively Correlated with Th17 Cells in Non-Small-Cell Lung Cancer Patients. Mediators Inflamm (2015) 0.77
Interleukin 17 is a chief orchestrator of immunity. Nat Immunol (2017) 0.77
Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis. Drug Des Devel Ther (2015) 0.77
Increased interleukin-17 transcripts in peripheral blood mononuclear cells, a link between T-helper 17 and proinflammatory responses in bladder cancer. Iran Red Crescent Med J (2015) 0.77
Eriobotrya japonica hydrophilic extract modulates cytokines in normal tissues, in the tumor of Meth-A-fibrosarcoma bearing mice, and enhances their survival time. BMC Complement Altern Med (2011) 0.77
IL-17B Can Impact on Endothelial Cellular Traits Linked to Tumour Angiogenesis. J Oncol (2010) 0.77
Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma. J Transl Med (2016) 0.76
Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model. PLoS One (2017) 0.75
The Membrane-Bound Form of IL-17A Promotes the Growth and Tumorigenicity of Colon Cancer Cells. Mol Cells (2016) 0.75
Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T Cells. J Immunol Res (2016) 0.75
Effect of IL-17 in the development of colon cancer in mice. Oncol Lett (2016) 0.75
N-Arylsulfonyl Indolines as Retinoic Acid Receptor-Related Orphan Receptor γ (RORγ) Agonists. ChemMedChem (2016) 0.75
Phenotypic and functional characterization of the major lymphocyte populations in the fruit-eating bat Pteropus alecto. Sci Rep (2016) 0.75
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
Interleukin-17 family members and inflammation. Immunity (2004) 16.16
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 10.53
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol (2006) 10.33
Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity (2002) 9.29
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med (2006) 7.87
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol (2006) 4.83
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J Exp Med (2008) 3.19
Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 3.02
Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol (2007) 2.21
T(H)-17: a giant step from T(H)1 and T(H)2. Nat Immunol (2005) 1.86
Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology (2001) 1.68
Immunology: what does it mean to be just 17? Nature (2006) 1.39
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res (2008) 1.38
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol (2008) 3.22
Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05
Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol (2006) 2.50
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol (2006) 2.36
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res (2004) 2.28
Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology (2009) 2.22
Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol (2007) 2.21
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res (2005) 2.06
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res (2007) 2.01
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol (2005) 1.96
Regulatory T-cell compartmentalization and trafficking. Blood (2006) 1.86
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 1.79
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity (2013) 1.77
IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol (2011) 1.76
Deciphering the role of Th17 cells in human disease. Trends Immunol (2011) 1.76
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res (2007) 1.66
Th17 cells in cancer: help or hindrance? Carcinogenesis (2011) 1.63
FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res (2009) 1.63
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology (2012) 1.47
Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res (2009) 1.39
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res (2008) 1.38
NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci U S A (2013) 1.35
Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res (2004) 1.35
Dual biological effects of the cytokines interleukin-10 and interferon-γ. Cancer Immunol Immunother (2011) 1.34
Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr (2013) 1.29
Prognostic significance of regulatory T cells in tumor. Int J Cancer (2010) 1.24
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci (Landmark Ed) (2009) 1.23
Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res (2011) 1.22
Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol (2008) 1.20
Bone marrow and the control of immunity. Cell Mol Immunol (2011) 1.15
A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease. J Immunol (2010) 1.14
Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J Immunol (2009) 1.12
Targeting regulatory T cells. Target Oncol (2012) 1.10
Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology (2012) 1.08
Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood (2007) 1.01
Synbindin in extracellular signal-regulated protein kinase spatial regulation and gastric cancer aggressiveness. J Natl Cancer Inst (2013) 1.01
Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int (2005) 0.99
Th17 cells have stem cell-like features and promote long-term immunity. Oncoimmunology (2012) 0.98
Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol (2012) 0.98
Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol (2008) 0.97
Toxoplasma gondii-infected human myeloid dendritic cells induce T-lymphocyte dysfunction and contact-dependent apoptosis. Infect Immun (2002) 0.97
Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii. Int J Parasitol (2004) 0.94
TLR2 mediates Helicobacter pylori-induced tolerogenic immune response in mice. PLoS One (2013) 0.93
Antigen-presenting cell (APC) subsets in ovarian cancer. Int Rev Immunol (2011) 0.93
Regulatory T cells in human ovarian cancer. J Oncol (2012) 0.90
Retracted Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer. J Pathol (2013) 0.90
Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinoma. J Immunother (2008) 0.90
Burkholderia and Cupriavidus spp. are the preferred symbionts of Mimosa spp. in southern China. FEMS Microbiol Ecol (2012) 0.87
Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. J Transl Med (2011) 0.86
A sensitive immunochromatographic assay using colloidal gold-antibody probe for rapid detection of pharmaceutical indomethacin in water samples. Biosens Bioelectron (2008) 0.85
Reduced N-cadherin expression is associated with metastatic potential and poor surgical outcomes of hepatocellular carcinoma. J Gastroenterol Hepatol (2012) 0.83
Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. Antimicrob Agents Chemother (2007) 0.83
The chemokine SDF-1/CXCL12 contributes to T lymphocyte recruitment in human pre-ovulatory follicles and coordinates with lymphocytes to increase granulosa cell survival and embryo quality. Am J Reprod Immunol (2005) 0.83